These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32757686)

  • 1. Machine learning derived genomics driven prognostication for acute myeloid leukemia with
    Shaikh AF; Kakirde C; Dhamne C; Bhanshe P; Joshi S; Chaudhary S; Chatterjee G; Tembhare P; Prasad M; Roy Moulik N; Gokarn A; Bonda A; Nayak L; Punatkar S; Jain H; Bagal B; Shetty D; Sengar M; Narula G; Khattry N; Banavali S; Gujral S; P G S; Patkar N
    Leuk Lymphoma; 2020 Dec; 61(13):3154-3160. PubMed ID: 32757686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy].
    Yu JQ; Xue SL; Li Z; Wang J; Wang C; Chu XL; Han R; Tao T; Qiu QC; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):210-215. PubMed ID: 32311890
    [No Abstract]   [Full Text] [Related]  

  • 3. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
    Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
    Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1.
    Srinivasan S; Dhamne C; Patkar N; Chatterjee G; Moulik NR; Chichra A; Pallath A; Tembhare P; Shetty D; Subramanian PG; Narula G; Banavali S
    Pediatr Blood Cancer; 2024 Feb; 71(2):e30791. PubMed ID: 38014874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
    Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
    Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia.
    Sun Y; Wang X; Chen WM; Hao Y; Li LD; Li JY; Sun K; Shi ZY; Jiang H; Jiang Q; Huang XJ; Qin YZ
    Hematol Oncol; 2024 Mar; 42(2):e3264. PubMed ID: 38461410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia.
    Hornung R; Jurinovic V; Batcha AMN; Bamopoulos SA; Rothenberg-Thurley M; Amler S; Sauerland MC; Berdel WE; Wörmann BJ; Bohlander SK; Braess J; Hiddemann W; Lehmann S; Mareschal S; Spiekermann K; Metzeler KH; Herold T; Boulesteix AL
    Sci Rep; 2018 Jul; 8(1):11293. PubMed ID: 30050054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
    Rücker FG; Agrawal M; Corbacioglu A; Weber D; Kapp-Schwoerer S; Gaidzik VI; Jahn N; Schroeder T; Wattad M; Lübbert M; Koller E; Kindler T; Götze K; Ringhoffer M; Westermann J; Fiedler W; Horst HA; Greil R; Schroers R; Mayer K; Heinicke T; Krauter J; Schlenk RF; Thol F; Heuser M; Ganser A; Bullinger L; Paschka P; Döhner H; Döhner K
    Blood; 2019 Nov; 134(19):1608-1618. PubMed ID: 31554635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
    Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
    Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
    Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
    Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
    Lee JW; Kim S; Jang PS; Chung NG; Cho B; Im SA; Kim M
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):e132-e139. PubMed ID: 31688618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
    Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
    Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia].
    Gao HT; Zhang Y; Sun K; Guo JM; Chen YQ; Chen XL; Shi J; Niu XN; Wang F; Huo L
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):210-215. PubMed ID: 28395444
    [No Abstract]   [Full Text] [Related]  

  • 17. AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR.
    XinhongYang ; Wu Y; Yang X; Wu X; Chen Y; Zhang R; Zhang Z
    Clin Lab; 2024 Mar; 70(3):. PubMed ID: 38469780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a Cryptic t(8;20;21)(q22;p13;q22) Resulting in RUNX1T1/RUNX1 Fusion in a Patient with Newly Diagnosed Acute Myeloid Leukemia.
    Macke EL; Meyer RG; Hoppman NL; Ketterling RP; Greipp PT; Xu X; Baughn LB; Shafer DA; He RR; Peterson JF
    Lab Med; 2022 Jul; 53(4):e87-e90. PubMed ID: 34791328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
    Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
    Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the therapeutic effect of avatinib bridged allogeneic hematopoietic stem cell transplantation on 7 cases of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia with KIT mutations].
    Han SY; Zhou HX; Han Y; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2024 Aug; 45(8):767-771. PubMed ID: 39307724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.